Combination drug therapy for high-risk bladder cancer that cannot be fully removed by surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two investigational drugs given together to treat high-risk non-muscle invasive bladder cancer that cannot be completely removed with standard surgery. The goal is to see if this combination can help control the cancer and avoid the need for bladder removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with high-risk non-muscle invasive bladder cancer.
- Your doctor has determined that the tumor is too large or widespread to be completely removed with a standard procedure called TURBT.
- You are not eligible for or have chosen not to have your bladder removed (radical cystectomy).
- You have had a TURBT procedure within the last 6 weeks.
- You are generally in good health, with a performance status of 0 to 2, meaning you can manage daily activities with some help if needed.
- Your organ function (blood counts, liver, kidney, heart) is within acceptable limits as determined by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) given before a second bladder surgery (re-TURBT) for people with high-risk non-muscle invasive bladder cancer that has high HER2 levels. The goal is to see if this approach improves outcomes compared to standard care.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.